lactoserum
ApprovedSmall molecule
Sanofilactoserum is one of 17 small molecule programs targeting Bacterial Vaginosis. It is currently in Approved.
1
Indications
7
Total Trials
0
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
65 competitors in Bacterial Vaginosis
#DrugCompanyPhaseTrials
1Acanya
PfizerApproved
Decadron
AAspen Global Incorporated
Approved
Mycostatin
GGood Molecules, LLC
Approved
N-Acetyl Cyteien
SStanford University
Approved
Lactobacillus Acidophilus
UUniversiteit Antwerpen
Approved
Tindamax
MMission Pharmacal
Phase 3
Conventional
PPopulation Health Research Institute
Phase 3
Lactoferrin
UUniversità degli Studi di Ferrara
Phase 3
Xifaxan
SSalix
Phase 2
lactoserum
SanofiApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Acceptability3 trials
Hygiene2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for lactoserum. EMBL-EBI & Wellcome Sanger Institute.
- [4]